During an investor event, KT&G announced its goal of generating more than 50% of its sales revenue from overseas operations by 2027.
The goal of this South Korean cigarette manufacturer is to achieve sales of 10 trillion Korean won ($8.1 billion) in a year, with a projected annual sales of 5.9 trillion Korean won ($4.8 billion) by 2022. Last year, approximately one-third of KT&G's sales may have come from foreign markets.
Bang Kyung-man, the executive vice president of KT&G, has announced that the company will not only focus on its combustible tobacco business but also strengthen its next-generation product (NGP) business, including heated tobacco products (HnB) and functional foods for health.
He stated, "We will invest KRW 40 trillion and construct new overseas production facilities over the next five years, while expanding existing facilities, to meet the continuous growth in NGP demand, such as HnB products.
Bang stated that the company is considering building a new factory in Kazakhstan or Eastern Europe. He mentioned that in order to raise the necessary funds, the company plans to sell unused properties and borrow from banks.
Since signing an agreement with PhiMo International in 2020 to commercialize KT&G's smoke-free products outside of Korea, KT&G has exported its HnB products to over 30 countries.
Currently, 90% of KT&G's revenue comes from cigarette sales, with the remaining 10% coming from their HnB products. The company has four tobacco manufacturing plants in South Korea, Russia, Turkey, and Indonesia, with a total annual production capacity of 13.6 billion cigarettes.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
